CS5001-101
12 Apr 2022
CS5001-101
NCT05279300
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas
Cstone
Cancer Type | All cancers; Lymphoma |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2022-03-28 |
Anticipated End Date | 2024-03-31 |
Hospital | Icon Cancer Centre - Tennyson and Windsor Garden |
---|---|
Clinical Trial Coordinator | Sue Yeend |
Sue.Yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Sarwan Bishnoi |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs